Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Tue Feb 06 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Smal ...
PDF (180 KB)
Tue May 08 00:00:00 GMT-04:00 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared ...
PDF (268 KB)
Wed Apr 04 00:00:00 GMT-04:00 2018
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Init ...
PDF (201 KB)
Fri Jun 01 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients wi ...
PDF (203 KB)
Mon Sep 24 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients wit ...
PDF (269 KB)
Wed Oct 17 00:00:00 GMT-04:00 2018
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patient ...
PDF (286 KB)
Tue Sep 25 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients ...
PDF (205 KB)
Wed Oct 03 00:00:00 GMT-04:00 2018
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types ...
PDF (101 KB)
Tue Oct 23 00:00:00 GMT-04:00 2018
Daiichi Sankyo, Inc. Publishes Second Edition of Pain Trends Report
PDF (211 KB)
Wed Nov 21 00:00:00 GMT-04:00 2018
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for FLT3 Inhibitor Quizartinib ...
PDF (246 KB)
Showing 1 - 10 of 43 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...